Abstract 268P
Background
In early breast cancer, residual disease after neoadjuvant chemotherapy is considered an important prognostic factor, especially for triple-negative breast cancer (TNBC) and HER2-positive patients. The CREATE-X study demonstrated a survival benefit of adjuvant capecitabine (adjC) for these patient groups, particularly in TNBC. Researchers have been trying to find the appropriate population for adjC as Real-World Evidence (RWE). However, RWE in the Asian population was lacking, and previous RWE studies were limited in number. In addition, these studies did not include patients who received neoadjuvant immunotherapy treatment, while the Keynote-522 trial demonstrated the benefit of immunotherapy in early TNBC. Therefore, we evaluated the advantages of adjC in non-pCR TNBC patient group by using RWD.
Methods
We conducted a retrospective analysis of 1,033 TNBC patients who received neoadjuvant treatment at Samsung Medical Center between 2018 and 2023, using de-identified, anonymous data from the institutional Clinical Data Warehouse. Among these patients, we identified 403 patients who received at least one cycle of adjC, while 36 received no adjuvant treatment. Residual Cancer Burden (RCB) classification were available for 399 patients. The primary outcome of the study was Disease-Free Survival (DFS). We conducted a survival analysis using Kaplan-Meier method.
Results
The median DFS has not yet been reached. The disease risk of the adjC group tended to be lower than that of the no adjuvant treatment group, but the difference was not statistically significant (Hazard ratio(HR), 0.52; p-value=0.083). At 36 months, 86% of patients in the adjC group were disease-free or alive, compared to 76% of patients in the no adjuvant treatment group. Compared to the RCB-I group (n=114, 28.4%), the HR for the RCB-II group (n=233, 58.5%) was 1.40, and the for the RCB-III group (n=52, 13.1%), it was 5.88 (p<0.0001). The DFS at 36 months was 90%, 89%, and 67% for the RCB-I, II, and III groups, respectively.
Conclusions
In this study, adjC demonstrated a potential survival benefit for non-pCR TNBC patients. Subgroup analysis based on RCB classification indicated a higher risk associated with higher RCB class.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by Future Medicine 2030 Project of the Samsung Medical Center [SMO1230451].
Disclosure
M.J. Kim: Financial Interests, Personal, Full or part-time Employment: Roche Korea. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, Novartis, MSD; Financial Interests, Institutional, Other, Research Grant: AstraZeneca, Pfizer, Roche, MSD; Non-Financial Interests, Principal Investigator: AstraZeneca, Pfizer, Novartis, MSD, Lilly, Roche, Daiichi Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
325P - Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival
Presenter: Yang Xu
Session: Poster session 02
326P - Sentinel lymph node mapping in breast cancer: Evaluating the dual-tracer method with indocyanine green and radioisotope
Presenter: Ava Kwong
Session: Poster session 02
328P - Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique
Presenter: Vanessa Petry
Session: Poster session 02
329P - Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy
Presenter: Jarle Karlsen
Session: Poster session 02
330P - Effect of radiotherapy in deep inspiration in patients with left breast cancer: Does the size of the target area affect the dose for the most crucial organs at risk?
Presenter: Zoltan Locsei
Session: Poster session 02
331P - miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ
Presenter: Tanja Marinko
Session: Poster session 02
332P - Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study
Presenter: Wei Li
Session: Poster session 02
333P - Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026)
Presenter: Maeve Hennessy
Session: Poster session 02